Challenging the Conventional Wisdom Around Doxorubicin in Soft Tissue Sarcoma
JCO Oncology Practice · 12.06.2026
DOI: 10.1200/op-26-00502 ↗Kurz gefasst
Editorial in der Zeitschrift JCO Oncology Practice, online erschienen am 12.06.2026. Verfasst von Jacob N Stein und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
A Brief History of Sarcoma and DoxorubicinSoft tissue sarcomas (STS) are characterized by their rarity, heterogeneity, and poor responsiveness to therapy.Less than 1% of all adult malignancies are sarcomas, comprising
Autor:innen und Institutionen
- Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
- Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
ORCID-Profile: Jacob N Stein, Mark G Woodcock, Kevin Y Chen
Förderung
- NCI NIH HHS
Zitieren
APA
Stein, J. N., Woodcock, M. G., & Chen, K. Y. (2026). Challenging the Conventional Wisdom Around Doxorubicin in Soft Tissue Sarcoma. JCO Oncology Practice. https://doi.org/10.1200/op-26-00502
Vancouver
Stein JN, Woodcock MG, Chen KY. Challenging the Conventional Wisdom Around Doxorubicin in Soft Tissue Sarcoma. JCO Oncology Practice. 2026. doi:10.1200/op-26-00502
BibTeX
@article{Stein2026,
author = {Stein, Jacob N and Woodcock, Mark G and Chen, Kevin Y},
title = {Challenging the Conventional Wisdom Around Doxorubicin in Soft Tissue Sarcoma},
journal = {JCO Oncology Practice},
year = {2026},
doi = {10.1200/op-26-00502}
}
EUVIMED